Home > Insider Trading > Filing (0001209191-22-058795)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1787297	Passage Bio Inc.	PASG	Biological Products, (No Disgnostic Substances) (2836)	822729751

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1799814	Alexandros Fotopoulos	One Commerce Square 2005 Market Street, 39Th Floor Philadelphia PA 19103	Chief Technical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-11-22	12,500	$0.00	23,965	No	4	M	Direct
Common Stock	Disposition	2022-11-22	3,720	$1.33	20,245	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2022-11-22	12,500	$0.00	12,500	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
37,500			No	4	M	Direct

Footnotes

Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
The reported total includes 3,082 shares of common stock the reporting person has acquired since the date of his last ownership report through the issuer's Employee Stock Purchase Plan in one or more transactions exempt pursuant to Rules 16b-3(c) and 16b-3(d).
The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
The reported transaction represents the settlement of restricted stock units which vested on June 15, 2022 but for which settlement was delayed due to an inadvertent administrative error.
1/4 of the RSUs vested on June 15, 2022, and the remainder will vest as to 1/4 of the total award in annual installments thereafter, subject to the Reporting Person's continued service to the Issuer on each vesting date.
These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date.